In the past years, several other highly specific EZH2 inhibitors have been characterized [8, 9, 27, 28], three of which were shown to cause highly similar changes in the gene expression profile when used on a lymphoma cell line [27], indicating a common mechanism of action both on-target and off-target. This evidence concerns the gene EZH2 and lymphoma.